Fresenius is a global healthcare group — which means facing different patient requirements on each continent and in each country. To overcome these complex challenges, we constantly hone our expertise and skills in the relevant target markets and medical sectors. Using modern technology and a sophisticated organization structure, we successfully work across national borders and bring our specialized knowledge to where it's needed. Over the years, we have built up an excellent network and are proud to be able to offer international opportunities to our employees.
Its product portfolio comprises a range of highly complex biopharmaceuticals, clinical nutrition, medical technologies, and I.V. generic drugs. Within biopharmaceuticals, Fresenius Kabi offers, among others, biosimilar drugs with a focus on autoimmune diseases and oncology. The company’s clinical nutrition portfolio includes a wide selection of enteral and parenteral nutrition products. In the segment of medical technologies, Fresenius Kabi offers vital disposables, infusions pumps, apheresis machines, cell therapy devices, and more.
Fresenius Kabi employs over 40,000 people worldwide. In 2025 the company reported sales of more than €8.5 billion. Fresenius Kabi AG is a wholly owned subsidiary of the Fresenius SE & Co. KGaA healthcare group and one of the two Operating Companies of Fresenius.
Helios Germany operates more than 80 hospitals, about 200 outpatient care centers with, six prevention centers and 30 occupational medicine centers. Helios treats approximately 5.6 million patients annually, of whom 4 million are outpatients. Since its beginnings, Helios has focused on measurable, high medical quality as well as data transparency and is better than the German average in more than 90 percent of the quality targets. With about 80,000 employees, Helios generated sales of €8.1 billion in 2025. With its own 35 training centers, Helios represents education and training in the healthcare sector. Helios Germany is headquartered in Berlin.
Quirónsalud has 57 hospitals, including seven in Latin America, around 130 outpatient centers and more than 300 occupational risk prevention centers, and treats approximately 22 million patients annually, of whom 20 million are outpatients. Quirónsalud has about 50,000 employees and generated sales of more than €5.4 billion in 2025.
As a company which is actively engaged in Group operations, Fresenius Holding's responsibility is to safeguard and build on this success by coordinating complex business processes throughout the Fresenius Group and managing centralized services for all business segments.
The Fresenius Group IT Department offers dependable IT services and solutions across the Fresenius Group.
Fresenius Health Services plans, builds and operates healthcare facilities in Germany and other European countries, ensuring the operation of complex technology in numerous hospitals.